ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors. NEW YORK, Oct. 13, 2026...
Covered in this story
Call it yourself
No calls on $AVBP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Arrivent Biopharma Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.